<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03571048</url>
  </required_header>
  <id_info>
    <org_study_id>18-0487</org_study_id>
    <nct_id>NCT03571048</nct_id>
  </id_info>
  <brief_title>Pilot Study of Time Restricted Feeding as a Weight Loss Intervention</brief_title>
  <official_title>Pilot Study of Time Restricted Feeding as a Weight Loss Intervention in Overweight and Obese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The circadian timing of Energy Intake (EI) has emerged as a key factor in the regulation of
      body weight. Studies have suggested that eating later in the evening or at night when the
      circadian system is promoting sleep adversely influences weight loss. In contrast,
      restricting EI to a short window during waking hours and extending the length of the
      overnight fast (i.e., time restricted feeding, TRF) may be a practical and useful weight loss
      strategy. The overall objective of this proposal is to provide a foundation to inform the
      design of a future large-scale trial to evaluate the efficacy of TRF in generating weight
      loss. The investigators aims are to: 1) Assess processes critical for the success of a
      large-scale trial comparing the efficacy of a reduced calorie diet with time restricted
      feeding (RCD+TRF) versus standard RCD on weight loss; 2) Develop methodology to assess
      compliance to the RCD+TRF versus standard RCD program and collect preliminary data on whether
      the programs have differential effects on free-living behaviors (EI, appetite, physical
      activity, and sedentary behavior); and 3) Measure metabolic responses to RCD+TRF versus
      standard RCD to determine candidate mechanisms related to weight loss at 12wks and weight
      maintenance at 6mo post-intervention. The investigators primary hypothesis is that weight
      loss will be greater in the TRF group compared to the RCD group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The circadian timing of energy intake (EI) has emerged as a key factor in the regulation of
      body weight. Studies have suggested that eating meals later in the evening or during the
      biological night when the circadian system is promoting sleep adversely influences the
      success of weight loss therapy. In contrast, restricting EI to a short window during waking
      hours and extending the length of the overnight fast (i.e., time restricted feeding, TRF) may
      be a practical and useful strategy for promoting weight loss and weight maintenance. However,
      potential benefits of adding TRF to a weight loss program have yet to be evaluated in a
      well-controlled clinical study. The overall objective of this proposal is to provide a
      foundation to inform the design of a future large-scale trial to evaluate the efficacy of TRF
      in generating weight loss. The investigators overall hypothesis is that feasibility,
      adherence, and acceptability of a weight loss intervention using TRF in the setting of a
      reduced calorie diet (RCD) - RCD+TRF - will be similar to compliance with an intervention
      using a reduced calorie diet alone (RCD), suggesting acceptability for a future large-scale
      trial. In this 12-week pilot and feasibility study, 30 overweight and obese individuals will
      be randomized 1:1 to RCD+TRF (EI restricted to a 10-hour window starting 1 hour from habitual
      waking time) or standard RCD (no restriction on feeding duration). Additional follow-up will
      occur at 6 months to collect pilot data on weight maintenance. Measures include feasibility,
      acceptability and adherence to the interventions, body weight, body composition (Dual-energy
      X-ray absorptiometry (DXA)), EI (smart phone application), physical activity (PA,
      accelerometery), glucose variability (continuous glucose monitoring, CGM), sleep
      (questionnaires and polysomnography), and nocturnal substrate metabolism (room calorimetry).
      The specific aims (SA) are as follows:

      Specific Aim 1a. To evaluate the feasibility and acceptability of a 12-week TRF intervention
      compared to a standard dietary weight loss intervention (i.e. RCD). Feasibility of enrollment
      and retention, and acceptability of the intervention will be assessed in adults with obesity
      meeting inclusion/exclusion criteria proposed for the future large-scale trial. The
      investigators will assess adherence to the weight loss programs, as measured objectively with
      a novel smartphone application and verified with CGM data, and subjectively with the use of
      questionnaires.

      Specific Aim 1b. To assess the efficacy of RCD+TRF compared to RCD alone in producing weight
      loss at 12 weeks and reducing the risk of weight regain after 6 months of follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Body Weight</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Body weight will be measured via clinic scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Body Composition</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Body composition will be assessed with dual-energy x-ray absorptiometry (DXA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Objectively Measured Energy Intake (Camera)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>All energy intake events will be recorded using the camera function on a cell phone application</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Objectively Measured Meal Timing (Camera)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Time stamps of all energy intake events will be recorded using the camera function on a cell phone application</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Resting Energy Expenditure (REE)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>REE will be measured using indirect calorimetry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Physical Activity</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Physical activity will be measured with activity monitors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Sedentary Behavior</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Sedentary behavior will be measured with activity monitors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in daily glucose patterns</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Measured using continuous glucose monitors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in free-living sleep patterns</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Sleep will be assessed by wrist actigraphy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Self-Reported Dietary Adherence</measure>
    <time_frame>Baseline and weeks 4, 8, 12</time_frame>
    <description>Adherence to prescribed diet will be assessed with a questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in appetite</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Appetite will be assessed with a Visual Analog Scale (VAS) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mood</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Mood will be assessed with questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Quality of life will be assessed with questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective measures of nocturnal energy expenditure</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Nocturnal energy expenditure will be measured by room calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective measures of sleep</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Sleep will be measured in the laboratory by polysomnography</description>
  </secondary_outcome>
  <other_outcome>
    <measure>6 Month Post-Intervention Follow-Up Body Weight</measure>
    <time_frame>24 weeks after completion of the 12-week intervention (i.e. at week 36)</time_frame>
    <description>Body weight will be measured via clinic scale.</description>
  </other_outcome>
  <other_outcome>
    <measure>6 Month Post-Intervention Follow-Up Body Composition</measure>
    <time_frame>24 weeks after completion of the 12-week intervention (i.e. at week 36)</time_frame>
    <description>Body composition will be assessed with dual-energy x-ray absorptiometry (DXA).</description>
  </other_outcome>
  <other_outcome>
    <measure>6 Month Post-Intervention Follow-Up Resting Energy Expenditure (REE) measurement</measure>
    <time_frame>24 weeks after completion of the 12-week intervention (i.e. at week 36)</time_frame>
    <description>REE will be measured using indirect calorimetry.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Reduced Calorie Diet (RCD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will focus on daily calorie restriction as their dietary weight loss strategy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Time Restricted Feeding (TRF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will focus on time restricted feeding in addition to daily calorie restriction as their dietary weight loss strategy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Reduced Calorie Diet (RCD)</intervention_name>
    <description>Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD.</description>
    <arm_group_label>Reduced Calorie Diet (RCD)</arm_group_label>
    <arm_group_label>Time Restricted Feeding (TRF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Time Restricted Feeding (TRF)</intervention_name>
    <description>Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD. Participants in this group will also instructed to eat only during a window of 10 hours, starting within 3 hours of waking. They will also be instructed in specific strategies to support TRF including: strategies to deal with hunger outside eating windows, distraction techniques, and choosing a balanced diet/appropriate portions during feeding windows.</description>
    <arm_group_label>Time Restricted Feeding (TRF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males and females with a BMI of 27-45 kg/m2 and weight stable over the previous
             6 months;

          -  Age, 18-50 years old;

          -  Passing medical and physical screening, and analysis of blood and urine screening
             samples;

          -  Typical eating duration &gt;12 hours per day (assessed by questionnaires);

          -  Own a smartphone

        Exclusion Criteria:

          -  Pregnancy or lactation for women (women who are &gt;6 months postpartum with no plans of
             becoming pregnant in the next year and who are not currently lactating can be
             included; oral contraceptives will be allowed if medication has been consistent for
             the prior 6 months)

          -  Postmenopausal women (menopausal status will be assessed during the history and
             physical, with requirement of self-reported regular menstrual cycles for the last
             year; women who have undergone hysterectomy but with ovaries in place who continue to
             have regular menstrual symptoms can be included)

          -  Being considered unsafe to participate as determined by the study physician;

          -  History of cardiovascular disease, diabetes, uncontrolled hypertension, untreated
             thyroid, renal, hepatic diseases, dyslipidemia or any other medical condition
             affecting weight or lipid metabolism;

          -  History of human immunodeficiency virus or hepatitis B or C (self-report);

          -  Taking medications affecting weight or energy intake/energy expenditure in the last 6
             months, including weight loss medications, antipsychotic drugs or other medications as
             determined by the study physician;

          -  Having abnormal blood chemistry (eGFR&lt;45mL/min, AST or ALT &gt;3 times the upper limit of
             normal) or as deemed significant by the study physician;

          -  Being a smoker or having been a smoker in the 3 months prior to their screening visit;

          -  Working night shifts;

          -  Extreme early or extreme late chronotype as determined by the Munich Chronotype
             questionnaire37;

          -  Night eating syndrome (at least 25% of food intake is consumed after the evening meal
             and/or at least two episodes of nocturnal eating per week) as assessed with meal
             pattern assessment questionnaire;

          -  For participants completing the PSG studies, greater than moderate sleep apnea (score
             high risk â‰¥ 2 or more categories on the Berlin Questionnaire). Participants completing
             the primary weight loss intervention will not be excluded based on Berlin OSA risk
             scores.

          -  For participants completing the PSG studies, use of medications affecting sleep
             (benzodiazepines and other sleep aids, as determined by study physician). Participants
             completing the primary weight loss intervention will not be excluded based on use of
             medications affecting sleep.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Thomas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado Anschutz Health and Wellness Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corey A Rynders, PhD</last_name>
    <phone>720-848-6461</phone>
    <email>TRF-Study@ucdenver.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Anschutz Health and Wellness Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corey Rynders, PhD</last_name>
      <phone>720-848-6461</phone>
      <email>TRF-Study@ucdenver.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 31, 2018</study_first_submitted>
  <study_first_submitted_qc>June 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2018</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

